close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Derm-Biome Pharmaceuticals, Inc

News headline image
Derm-Biome’s DB-007-5 is highly effective at treating atopic dermatitis and reducing itch in preclinical study, outperforming the current leading topical AD drug
From Derm-Biome Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Derm-Biome Pharmaceuticals adds Dr. Jerry Tan, internationally renowned expert in acne and acne scarring, to its Scientific Advisory Board
From Derm-Biome Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Derm-Biome Pharmaceuticals to develop skincare treatment that promotes skin health and longevity
From Derm-Biome Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Derm-Biome Pharmaceuticals and TransBIOtech awarded $450,000 Applied Research and Development (ARD) grant funding
From Derm-Biome Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Derm-Biome Pharmaceuticals’ topical therapy shows positive results in preclinical skin cancer trial: drug prevents the development of precancerous skin conditions and treats existing skin cancers with no observable side effects.
From Derm-Biome Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Derm-Biome Pharmaceuticals prepares to begin IND-enabling studies for DB-007-4, a potential best-in-class treatment for inflammatory skin diseases
From Derm-Biome Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Derm-Biome Pharmaceuticals Announces Collaboration with Massachusetts General Hospital in Skin Cancer Study
From Derm-Biome Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Derm-Biome Pharmaceuticals to Present at the 2023 OBIO Investment Summit on February 10, 2023
From Derm-Biome Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Derm-Biome Pharmaceuticals’ Multi-Target Topical Drug Produces Positive Results in Preclinical Study in Acne
From Derm-Biome Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Derm-Biome Pharmaceuticals, Inc. reports positive preclinical data in melanoma and squamous cell carcinoma, initiates a program aimed at advancing topical therapies for skin cancer to the clinic
From Derm-Biome Pharmaceuticals, Inc
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today